... of the company's stock valued at $277,000 after buying an additional 4,556 shares during the last quarter. Finally, Ardsley Advisory Partners bought a new stake in shares of Karyopharm Therapeutics during the second quarter valued at approximately ...
https://www.americanbankingnews.com/2018/09/02/zacks-brokerages-expect-karyopharm-therapeutics-inc-kpti-will-post-earnings-of-0-88-per-share.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+AmericanBankingNews+%28American+Banking+News%29
No comments:
Post a Comment